Watson Acquires Three Contraceptives From Searle

Watson Laboratories, Inc. has acquired the U.S. rights to three contraceptive products from G.D. Searle & Co., a subsidiary of Monsanto Co. The acquisition of Tri-Norinyl, Norinyl and Brevicon by the Watson Pharmaceuticals subsidiary cost $120 million in cash.

Watson Labs and Searle also entered into a supply agreement under which Watson will have the right to purchase these products from Searle for three years; the first two years in finished package form and the third year in bulk tablet form.

For more information: Watson Pharmaceuticals, Inc., 311 Bonnie Circle, Corona, CA 91720, USA.